期刊文献+

组蛋白去乙酰化酶抑制剂LBH589对急性髓系白血病细胞株HL60/ADM增殖、凋亡及耐药的影响 被引量:1

Effect of histone deacetylase inhibitor LBH589 on proliferation, apoptosis and drug resistance of acute myeloid leukemia cell line HL60/ADM
原文传递
导出
摘要 目的 探讨组蛋白去乙酰化酶抑制剂LBH589对急性髓系白血病细胞株HL660/ADM的增殖、凋亡和耐药的影响.方法 采用不同浓度LBH589处理耐药的HL60/ADM细胞,四甲基偶氮唑蓝(MTT)法检测细胞增殖和多柔比星作用24h IC50值,AnnexinV-FITC/PI荧光染色流式细胞术检测细胞凋亡、多柔比星摄取率和多药耐药蛋白1(MRP1)表达,评估LBH589逆转耐药效应.Westemblot检测p53、Akt、p-Akt、组蛋白-3、乙酰化组蛋白-3、β-actin蛋白表达.结果 10~80 nmol/L LBH589能够抑制HL60/ADM细胞增殖和诱导凋亡,70 nmol/LLBH589作用60 h抑制效果最佳.20 nmol/LLBH589显著下调HL60/ADM细胞表面MRP1的表达[(93.90±4.20)%比(76.19±6.53)%,P<0.05]、提高HL60/ADM细胞多柔比星摄取率[(8.53±0.68)%比(25.67±1.34)%,P< 0.01]、降低多柔比星24 hIG0值[(6.833±0.319) μg/ml比(1.382±0.104)μg/ml,P< 0.01],其逆转耐药倍数为4.9倍.LBH589处理HL60/ADM细胞24、48 h,乙酰化组蛋白-3相对表达水平均高于LBH589处理前(P<0.01),处理后24h和48 h p-Akt相对表达水平分别为1.07±0.09和0.59±0.01,低于处理前表达水平(2.03±0.12)(P<0.01),p53蛋白相对表达水平分别为0.57±0.04和1.31±0.09,明显高于处理前的表达(0.21±0.02)(P< 0.01).结论 LBH589通过阻断PI3K-Akt通路、下调其MRP1的表达及提高多柔比星摄取率有效地抑制HL60/ADM细胞的增殖和诱导其凋亡,并逆转其耐药. Objective To investigate the effect of histone deacetylase inhibitor LBH589 on proliferation,apoptosis and drug resistance of chemoresistant acute myeloid leukemia cells HL60/ADM.Methods HL60/ADM cells were treated with LBH589.Proliferation,apoptosis and adriamycin IC50 were evaluated by MTT assay and AnnexinV-FITC/PI stain.The change in MRP1 expression and intercellular adriamycin accumulatiom were analyzed by flow cytometry.Results Effective proliferative inhibition and apoptotic induction in HL60/ADM cells were observed after treatment with 10-80 nmol/L LBH589 with maximal effect detected after treatment with 70 nmol/L LBH589 for 60 hours.However,inhibition ratio remain unchanged with the further increase of drug dose and incubation time (P > 0.05).Downregulation of MRP1 [(93.90±4.20) % vs (76.19±6.53) %],upregulation of adriamycin accumulation [(8.53±0.68) % vs (25.67±1.34) %] and decrease in adriamycin IC50 [(6.833±0.319) μg/ml vs (1.382±0.104) μg/ml] were induced by the treatment with 20 nmol/L LBH589 (P < 0.01),whose reversal fold was 4.9.The expression of acetylated histone 3 after treatment with LBH589 was higher than that before treatment (P < 0.01).However,relative p-Akt levels after treatment for 24 h and 48 h were 1.07±0.09 and 0.59±0.01,respectively,which were lower than that before treatment (2.03±0.12) (P < 0.01).Meanwhile,expression levels of p53 were 0.57±0.04 and 1.31±0.09,respectively,which were higher than that before treatment (0.21 ±0.02) (P < 0.01).Conclusion Treatment with LBH589 has the capability of inhibiting proliferation and inducing apoptosis,as well as increasing intercellular adriamycin accumulation and sensitivity through downregulation of MRP1 expression and inhibition of PI3K-Akt signaling pathway in HL60/ADM cells.
出处 《白血病.淋巴瘤》 CAS 2014年第4期199-203,共5页 Journal of Leukemia & Lymphoma
关键词 白血病 组蛋白脱乙酰基酶抑制剂 细胞增殖 凋亡 抗药性 肿瘤 Leukemia Histone deacetylase Inhibitor Cell proliferation Apoptosis Drug resistance, neoplasm
  • 相关文献

参考文献13

  • 1Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges[J]. Cancer Lett, 2009, 280: 233- 241.
  • 2George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBHS$9 and the hsp90 inhibitor 17-AAG ishighly active against human CML-BC cells and AML cells with activating mutation of FLT-3[J]. Blood, 2005, 105: 1768-1776.
  • 3Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic maliguancies[J]. Clin Cancer Res, 2006, 12: 4628-4635.
  • 4王彩霞,毛平,杜庆华,王顺清,李庆山,张玉平,应逸,莫文健,周志衡.急性白血病组蛋白乙酰化修饰及其对错配修复基因表达的调控作用[J].白血病.淋巴瘤,2011,20(3):132-136. 被引量:2
  • 5Esteller M. Cancer epigenomics: DNA methylomes and histone- modification maps[J]. Nat Rev Genet, 2007, 8: 286-298.
  • 6Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance[J]. Cancer Res, 2006, 66: 5781-5789.
  • 7Fiskus W, Pranpat M, Balasis M, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia ceils [J]. Mol Cancer Ther, 2006, 5:3096-3104.
  • 8Hasegawa H, Yamada Y, Tsukasaki K, et al. LBHS89, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway [J]. Leukemia, 2011, 25: 575-587.
  • 9Yu C, Rahmani M, Almenara J, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells[J]. Cancer Res, 2003, 63: 2118-2126.
  • 10Tazzari PL, Cappellini A, Ricci F, et al. Multidrug resistance- associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blast[J]. Leukemia, 2007, 21: 427-438.

二级参考文献28

  • 1王楠,阎征,刘娜.组蛋白去乙酰酶抑制剂的药理学研究进展[J].中国新药杂志,2004,13(7):594-598. 被引量:2
  • 2黄轶群,马旭东.组蛋白乙酰化与白血病[J].白血病.淋巴瘤,2006,15(2):145-148. 被引量:2
  • 3王生余,张旭辉,于晓妉.新型抗肿瘤药物组蛋白去乙酰化酶抑制剂[J].国际肿瘤学杂志,2006,33(6):404-406. 被引量:12
  • 4Rebel VI, Kung AL, Tanner EA, et al. Distinct roles for CREBbinding protein and p300 in hematopoiet stem cell-renewal. Proc Nad Aead Sci USA, 2002, 99: 14789-14794.
  • 5Inoue Y, Itoh Y, Abe K, et al. Smad3 is acetylated by p300/CBP to regulate its transaetivation activity. Oneogene, 2007, 26: 500-508.
  • 6Han J, Zhou H, Li Z, et 81. The Rtt109-Vps75 historic acetyltransferase complex acetylates non-nucleosomal histone H3. J Biol Chem, 2007, 282: 14158-14164.
  • 7Eherharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep, 2002, 3: 224-229.
  • 8Lorincz MC, Schubeler D, Groudine M. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol Cell Biol, 2001, 21: 7913-7922.
  • 9Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors from target to clinical trials. Expert Opin lnvestig Drugs, 2002, 11: 1695-1713.
  • 10Johnstnne RW. Histone-eaeelylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 2002, 1: 287-299.

共引文献4

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部